Business
LP-LDL? news media interest in USA
LP-LDL? news media interest in USA.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \nRNS Number : 6145M OptiBiotix Health PLC 01 May 2018 \n\nOptiBiotix Health plc\n(\"OptiBiotix\" or the \"Company\")\n \nLP-LDL® news media interest in USA\nOptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has become aware of news reports on its LP-LDL® product in the USA. The media interest has been generated by a potential commercial partner, Seed Health, who have purchased LP-LDL® for use in its multi-strain product which is intended for launch in the USA in May 2018.\n \nSeed have developed an innovative product concept which combines multiple strains of different probiotics which have been selected because of strong clinical trial data. The news report refers to clinical studies published in the scientific journal PLOS One (\"PLOS\") showing that one of the probiotics contained in Seeds multi-strain product reduced LDL or \"bad\" cholesterol and increased HDL or \"good\" cholesterol.\n \nOptiBiotix reported (RNS: 7 April 2016) and subsequently published the results of its human studies in PLOS in December 2017 and at international conferences demonstrating statistical and clinical significant reductions in cholesterol and blood pressure. These presentations and publications won best scientific publications at both ProBiota 2017 and ProBiota 2018, and have raised OptiBiotix's international profile, attracting strong commercial interest in LP-LDL®.\n \nThe article in Business Insider US provides a link to OptiBiotix's publication and discloses the use of LP-LDL® in Seeds product. OptiBiotix can confirm it is in discussions with Seed to agree commercial terms for the use of its LP-LDL® strain in Seeds products in preparation for a May launch in the USA. Whilst these negotiations are at an advanced stage, they are one of a number of discussions with US partners which may or may not progress to legal agreement. If or when commercial terms are concluded, a further announcement with be made.\n \nStephen O'Hara, CEO of OptiBiotix, commented: \"We are pleased that the strong science, successful human studies and international awards at major scientific conferences have attracted international commercial and media interest in LP-LDL®. This has allowed OptiBiotix to sign manufacturing, formu...